The WHO PQ team has announced the prequalification of a second mifepristone product, expanding the options of quality products for safe pregnancy termination that are available for procurement (see full list of prequalified reproductive health medicines here). The product in question is manufactured by Exelgyn in France.
Recent Posts
- An age-old problem with a need for renewed attention: new report calls for innovative R&D to tackle iron deficiency anaemia during pregnancy
- ...
- Concept Foundation and partners lead the largest ever trial study on use of aspirin to prevent pre-eclampsia, investigating optimal dosage and risks of blood loss.
- ...
- Concept Foundation partner Xianju Pharma achieves WHO Prequalification of its sterile MPA active ingredient – offering a new API source for long-acting injectable contraception
- ...
- Concept Foundation and WACI Health partner to save lives of women and girls in Africa
- ...
- International Universal Health Coverage Day: Concept Foundation continues to deliver research and solutions to achieve affordable SRH services for all
- ...
- An age-old problem with a need for renewed attention: new report calls for innovative R&D to tackle iron deficiency anaemia during pregnancy
- Concept Foundation and partners lead the largest ever trial study on use of aspirin to prevent pre-eclampsia, investigating optimal dosage and risks of blood loss.
- Concept Foundation partner Xianju Pharma achieves WHO Prequalification of its sterile MPA active ingredient – offering a new API source for long-acting injectable contraception
- Concept Foundation and WACI Health partner to save lives of women and girls in Africa
- International Universal Health Coverage Day: Concept Foundation continues to deliver research and solutions to achieve affordable SRH services for all